01895nas a2200337   4500000000100000008004100001260001300042653001000055653003100065653002400096653003800120653001100158653001600169653001100185653002100196653001000217653001200227653000900239653001600248653002500264653003000289653003200319100001200351700001200363700001300375245009400388300001100482490000700493520104300500022001401543       1998                            d  c1998 Apr10aAdult10aAntibodies, Anti-Idiotypic10aAntigens, Bacterial10aEnzyme-Linked Immunosorbent Assay10aFemale10aGlycolipids10aHumans10aImmunoglobulin A10aIndia10aleprosy10aMale10aMiddle Aged10aMycobacterium leprae10aPredictive Value of Tests10aSensitivity and Specificity1 aKumar B1 aSinha R1 aSehgal S00aHigh incidence of IgG antibodies to phenolic glycolipid in non-leprosy patients in India.  a238-410 v253 a<p>Purified phenolic glycolipid (PGL-1) from Mycobacterium leprae was used to detect IgG antibodies against PGL-1 in leprosy patients in an enzyme-linked immunosorbent assay (ELISA). A total of 698 sera were screened; they came from patients suffering from leprosy, autoimmune disease, myeloma, tuberculosis and sexually transmitted diseases (STDs). Cases with miscellaneous diseases and persons undergoing AIDS screening were also included. Sera from lepromatous and tuberculoid leprosy patients gave positivity rates of 60.5% and 41.7%, respectively. In non-leprosy cases, the PGL-1 ELISA showed an overall positivity rate of 6.9%; this was greatest in patients with tuberculosis (43.8%) followed by autoimmune diseases (40.9%) and miscellaneous cases including liver diseases (37.9%). This study emphasizes that PGL-1 ELISA has a low predictive value for diagnosis of active infection by Mycobacterium leprae. Positive reactions in a significant percentage of patients with autoimmune disease are intriguing and need indepth study.</p>  a0385-2407